Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19592088 | 0.95 | ROCK2 (0.48) | CYP1A2TDP1ROCK2ROCK1SYK | |
| SCHEMBL24353609 | 0.89 | ROCK2 (0.47) | CYP1A2TDP1ROCK2ROCK1 | |
| SCHEMBL24464185 | 0.83 | ROCK2 (0.47) | CYP1A2TDP1ROCK2ROCK1 | |
| SCHEMBL24862317 | 0.81 | ROCK2 (0.45) | CYP1A2TDP1ROCK2ROCK1 | |
| SCHEMBL21451348 | 0.81 | ROCK2 (0.67) | CYP1A2TDP1ROCK2ROCK1 | |
| SCHEMBL20661284 | 0.81 | ROCK2 (0.71) | CYP1A2TDP1ROCK2ROCK1 | |
| SCHEMBL24862643 | 0.80 | ROCK2 (0.57) | CYP1A2TDP1ROCK2ROCK1SYK | |
| SCHEMBL15638576 | 0.80 | ROCK2 (0.68) | ROCK2ROCK1 | |
| SCHEMBL24862299 | 0.79 | ROCK2 (0.48) | CYP1A2TDP1ROCK2ROCK1 | |
| SCHEMBL19592089 | 0.78 | ROCK2 (0.46) | CYP1A2TDP1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | CYP1A2 119/4885TDP1 3067/4885ROCK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.